Skip navigation

Strategies and Best Practices to Strengthen Program Compliance, Effectively Communicate with Stakeholders and Prevent Revenue Leakage

August 21-22, 2018
  • Arlington, VA

With evolving regulations impacting 340B programs, pharmaceutical companies are faced with uncertainty on how to strengthen program compliance and integrity. CBI’s 4th Annual 340B Manufacturer Summit breaks down and clarifies the impending regulations, provides strategies to develop comprehensive self-disclosure response and auditing processes, and establish best practices to collaborate with contract pharmacies and covered entities.

2018 brings an unprecedented focus by Congress and the Trump Administration on the size, purpose and integrity of the 340b program. Hear from National experts as the policy discussions and opportunities for input continue to evolve. From the President’s Blue Print on Drug Prices to the recently released HHS RFI, 340B remains a hot topic.

Critical Updates, Interactive Discussions
and Valuable Takeaways:

  • Gain insight on both manufacturer and covered entity interpretations of patient definition
  • Hear from industry experts as they navigate 2018 legislative, regulatory and legal attempts to course correct 340B
  • Uncover best practices to respond to covered entities and initiate “good faith” financial remediation
  • Explore the impact of patient definition outlined in the repealed Mega-Guidance
  • Recognize scenarios which lend themselves to miscommunication due to inconsistency in the terminology used by manufacturers versus other stakeholders
  • Determine what manufacturers are protected against related to diversions and duplicate discounts
  • Ask questions and engage in discussion to explore solutions to top manufacturer challenges

Previous Attendee Acclaim:

The lineup of speakers for the program were top notch.
The meeting was timely and gave plenty of
opportunities to network with attendees.

President, Apexus

Outstanding conference for me as a new person to 340B.

Regional Account Manager, Helsinn Therapeutics

As always, CBI delivered a conference filled with
quality content and subject matter experts
in the government programs field.

Director, Contracts & Pricing, Acorda Therapeutics, Inc.

The CBI Conference was outstanding — very informative
and timely topics covering the hot industry trends.
Very worthwhile event to attend.

Executive Director, Finance, Merck

The program was beyond a value-add. The mix of knowledge with the presenters provided something for every participant.

Manager, Strategic Contracting, Johnson & Johnson

340B Manufacturer Summit

Strategies and Best Practices to Strengthen Program Compliance, Effectively Communicate with Stakeholders and Prevent Revenue Leakage

With evolving regulations impacting 340B programs, pharmaceutical companies are faced with uncertainty on how to strengthen program compliance and integrity. CBI’s 4th Annual 340B Manufacturer Summit breaks down and clarifies the impending regulations, provides strategies to develop comprehensive self-disclosure response and auditing processes, and establish best practices to collaborate with contract pharmacies and covered entities.

2018 brings an unprecedented focus by Congress and the Trump Administration on the size, purpose and integrity of the 340b program. Hear from National experts as the policy discussions and opportunities for input continue to evolve. From the President’s Blue Print on Drug Prices to the recently released HHS RFI, 340B remains a hot topic.

Critical Updates, Interactive Discussions
and Valuable Takeaways:

  • Gain insight on both manufacturer and covered entity interpretations of patient definition
  • Hear from industry experts as they navigate 2018 legislative, regulatory and legal attempts to course correct 340B
  • Uncover best practices to respond to covered entities and initiate “good faith” financial remediation
  • Explore the impact of patient definition outlined in the repealed Mega-Guidance
  • Recognize scenarios which lend themselves to miscommunication due to inconsistency in the terminology used by manufacturers versus other stakeholders
  • Determine what manufacturers are protected against related to diversions and duplicate discounts
  • Ask questions and engage in discussion to explore solutions to top manufacturer challenges

Previous Attendee Acclaim:

The lineup of speakers for the program were top notch.
The meeting was timely and gave plenty of
opportunities to network with attendees.

President, Apexus

Outstanding conference for me as a new person to 340B.

Regional Account Manager, Helsinn Therapeutics

As always, CBI delivered a conference filled with
quality content and subject matter experts
in the government programs field.

Director, Contracts & Pricing, Acorda Therapeutics, Inc.

The CBI Conference was outstanding — very informative
and timely topics covering the hot industry trends.
Very worthwhile event to attend.

Executive Director, Finance, Merck

The program was beyond a value-add. The mix of knowledge with the presenters provided something for every participant.

Manager, Strategic Contracting, Johnson & Johnson